Spots Global Cancer Trial Database for pasireotide
Every month we try and update this database with for pasireotide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | NCT02060383 | Cushing's Disea... Acromegaly | Pasireotide s.c... Sitagliptin Liraglutide Insulin Pasireotide LAR Metformin | 18 Years - | Novartis | |
| Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease | NCT00434148 | Cushing's Disea... | Pasireotide | 18 Years - | Novartis | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | NCT01488487 | Advanced Adult ... | Everolimus Pasireotide | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease | NCT00171951 | Cushing Disease | Pasireotide | 18 Years - | Novartis | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease | NCT01915303 | Cushings Diseas... | Pasireotide wit... | 18 Years - | Novartis | |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01468532 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | docetaxel pasireotide prednisone | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer | NCT01356862 | Breast Cancer | PASIREOTIDE PLACEBO | 18 Years - | Alliance Pour La Recherche en Cancerologie | |
| Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | NCT01364415 | Neuroendocrine ... | Pasireotide LAR | 18 Years - | Novartis | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | NCT01620138 | Non-functioning... Prolactinomas | Pasireotide cabergoline | 18 Years - | Universidade Federal do Rio de Janeiro | |
| Pasireotide Therapy in Patients With Nelson's Syndrome | NCT01617733 | Nelson Syndrome | Pasireotide | 18 Years - 80 Years | Sheffield Teaching Hospitals NHS Foundation Trust | |
| Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | NCT01313559 | Castrate Resist... Chemotherapy Na... Prostate Cancer | Pasireotide Everolimus Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | NCT01620138 | Non-functioning... Prolactinomas | Pasireotide cabergoline | 18 Years - | Universidade Federal do Rio de Janeiro | |
| Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | NCT01374451 | Islet Cell Tumo... | Everolimus Pasireotide LAR | 18 Years - | Novartis | |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | NCT02060383 | Cushing's Disea... Acromegaly | Pasireotide s.c... Sitagliptin Liraglutide Insulin Pasireotide LAR Metformin | 18 Years - | Novartis | |
| Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease | NCT01374906 | Cushing's Disea... | pasireotide LAR SOM230 LAR 30 m... SOM230 LAR 10 m... | 18 Years - | Novartis | |
| Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | NCT01469572 | Neuroendocrine ... | Pasireotide Sir-sphere Radi... Everolimus | 18 Years - | Emory University | |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly | NCT01137682 | Acromegaly | Pasireotide octreotide LAR ... lanreotide ATG ... | 18 Years - | Novartis | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer | NCT01270321 | Thyroid Cancer | Everolimus Pasireotide Everolimus and ... | 18 Years - | Emory University | |
| HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications | NCT02775227 | Pancreatic Fist... Pancreatic Neop... | Hydrocortisone Pasireotide | 18 Years - | Helsinki University Central Hospital | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| SOM230 Ectopic ACTH-producing Tumors | NCT02780882 | Ectopic ACTH Sy... | Pasireotide | 18 Years - | Cedars-Sinai Medical Center | |
| Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess | NCT00994110 | Pancreatic Canc... | Pasireotide (SO... placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| Pasireotide Treatment for Neuroendocrine Tumor | NCT02779257 | Gastro-enteropa... | Pasireotide Diazoxide | 18 Years - 75 Years | University of Maryland, Baltimore | |
| Pasireotide Treatment for Neuroendocrine Tumor | NCT02779257 | Gastro-enteropa... | Pasireotide Diazoxide | 18 Years - 75 Years | University of Maryland, Baltimore | |
| A Study of Pasireotide in People With Prolactinoma | NCT06295952 | Prolactin-Produ... | Pasireotide SF-36 and HADS | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | NCT01469572 | Neuroendocrine ... | Pasireotide Sir-sphere Radi... Everolimus | 18 Years - | Emory University | |
| IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | NCT01234974 | Multiple Myelom... | Pasireotide Everolimus | 18 Years - | Milton S. Hershey Medical Center | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | NCT01620138 | Non-functioning... Prolactinomas | Pasireotide cabergoline | 18 Years - | Universidade Federal do Rio de Janeiro |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
